A Bold Alternative to Opioids
Advancing pain relief with innovative, data-driven treatments.
Advancing pain relief with innovative, data-driven treatments.
A biotechnology company dedicated to developing non-opioid pain relief solutions, Alyea Therapeutics focuses on Complex Regional Pain Syndrome (CRPS) and other chronic pain conditions.
Spearheaded by Dr. Amol Soin, Alyea intends to transform pain management through innovation. Alyea’s proprietary lead product and key offering, Low Dose Naltrexone (LDN), will be entering late-stage clinical trials, significantly holding FDA orphan drug designation. Orphan status offers such benefits as market exclusivity, tax credits, and streamlined regulatory support. Alyea Therapeutics is a wholly owned subsidiary of ALT 5 Sigma Corporation (Nasdaq:ALTS) with plans to be spun out in the first half of 2025 as its own stand alone public company.
Learn MoreNearly 20.9% of U.S. adults (51.6 million people) experience chronic pain, according to the U.S. Centers for Disease Control and Prevention (CDC).
The CDC estimates more than 108,000 drug overdose deaths occur each year.
Synthetic opioids were involved in an estimated 87% of opioid and 65% of all drug overdose deaths.
Alyea’s goal is revolutionizing pain management by advancing innovative solutions for the effective treatment of Complex Regional Pain Syndrome (CRPS). Our mission is improving the quality of life for patients globally and we are committed to innovative science.
Alyea’s leader, Amol Soin, MD, is widely recognized as a thought leader and innovator in pain management. He has served as president of the American Society of Interventional Pain Physicians, along with several other state and national organizations, shaping the future of his field through leadership and advocacy. Dr. Soin is a published author, having written a medical textbook and over 100 peer-reviewed publications. He holds several dozen patents worldwide for medical devices and pharmaceutical compounds designed to treat pain without opioids. Academically, Dr. Soin holds five degrees, including two from Ivy League institutions–Dartmouth and Brown. In addition to his medical and scientific contributions, he served as president of the Ohio Medical Board, where he played a key role in passing statewide regulations to combat the opioid crisis. With a career dedicated to innovation, leadership, and patient-centered solutions, Dr. Soin continues to drive advancements in pain management.
An investigational next-generation, non-opioid treatment, LDN targets inflammation and pain pathways to provide lasting relief without addiction risks.
Learn More
A next-generation topical pain relief technology, designed for targeted, non-invasive treatment with strong market potential.
Learn MoreFor more information about Alyea Therapeutics and its novel drug therapy, please click here.
Learn More
